CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the ...

CSL Ltd. plunged the most on record after the Australian biotechnology company cut its full-year outlook and flagged about $5 ...

The global biotechnology company will brief analysts on its latest downgrade on Monday morning after a horror year for the ...

Recent CSL Ltd (ASX: CSL) results disappointed, leading to short-term pressure on the share price. However, certain quality ...

CSL now expects weaker full-year revenue and profit as plasma, China pricing, and Vifor pressures weigh on performance.

- Deal accelerates the addition of clazakizumab, an anti-IL6 MAB currently in phase III development for treatment of chronic active antibody-mediated rejection, into CSL Behring's portfolio KING OF ...

The broker has been looking over the biotech giant's guidance downgrade. The post 'Blood on the Street': What is Bell Potter saying about the CSL share price crash? appeared first on The Motley Fool ...

The Pennsylvania biotech company CSL Behring says it is on track to file for approval of its hemophilia B gene therapy by the end of June after releasing pivotal data showing statistical superiority ...

SYDNEY--Pharmaceutical company CSL on Monday downgraded its annual earnings guidance and signaled another $5 billion of pretax impairments, including for the Vifor business that it acquired for $11.7 ...

Moscow opening reinforces CSL Behring's promise to deliver its world-class therapies to patients with rare and serious diseases around the world. KING OF PRUSSIA, Pa. — 08 December 2015 - Global ...